Rucaparib, another PARPi, has also shown promise in treating prostate cancer patients with PALB2 somatic mutations with a response rate of 100% in mCRPC as seen in the phase 2 TRITON2 study [107]. This evidence concerns the gene PALB2 and prostate carcinoma.